324 related articles for article (PubMed ID: 25869102)
1. Targeted therapies for advanced Ewing sarcoma family of tumors.
Jiang Y; Ludwig J; Janku F
Cancer Treat Rev; 2015 May; 41(5):391-400. PubMed ID: 25869102
[TBL] [Abstract][Full Text] [Related]
2. Investigational therapies for Ewing sarcoma: a search without a clear finding.
Vornicova O; Bar-Sela G
Expert Opin Investig Drugs; 2016 Jun; 25(6):679-86. PubMed ID: 26988130
[TBL] [Abstract][Full Text] [Related]
3. Ewing sarcoma: prognostic criteria, outcomes and future treatment.
Leavey PJ; Collier AB
Expert Rev Anticancer Ther; 2008 Apr; 8(4):617-24. PubMed ID: 18402528
[TBL] [Abstract][Full Text] [Related]
4. Update in treatment and targets in Ewing sarcoma.
Cote GM; Choy E
Hematol Oncol Clin North Am; 2013 Oct; 27(5):1007-19. PubMed ID: 24093173
[TBL] [Abstract][Full Text] [Related]
5. Prospects and challenges for the development of new therapies for Ewing sarcoma.
Grohar PJ; Helman LJ
Pharmacol Ther; 2013 Feb; 137(2):216-24. PubMed ID: 23085431
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
7. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
8. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.
Pappo AS; Patel SR; Crowley J; Reinke DK; Kuenkele KP; Chawla SP; Toner GC; Maki RG; Meyers PA; Chugh R; Ganjoo KN; Schuetze SM; Juergens H; Leahy MG; Geoerger B; Benjamin RS; Helman LJ; Baker LH
J Clin Oncol; 2011 Dec; 29(34):4541-7. PubMed ID: 22025149
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
[TBL] [Abstract][Full Text] [Related]
10. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
11. Potential approaches to the treatment of Ewing's sarcoma.
Yu H; Ge Y; Guo L; Huang L
Oncotarget; 2017 Jan; 8(3):5523-5539. PubMed ID: 27740934
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation profiling opens a new phase in the search of targeted therapy against Ewing sarcoma.
Rello-Varona S; Tirado OM
Pharmacogenomics; 2017 Sep; 18(14):1307-1309. PubMed ID: 28832268
[No Abstract] [Full Text] [Related]
13. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
Vormoor B; Curtin NJ
Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
[TBL] [Abstract][Full Text] [Related]
15. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
16. Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience.
Orr WS; Denbo JW; Billups CA; Wu J; Navid F; Rao BN; Davidoff AM; Krasin MJ
Ann Surg Oncol; 2012 Nov; 19(12):3816-22. PubMed ID: 22739653
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
19. Ewing's sarcoma: overcoming the therapeutic plateau.
Subbiah V; Kurzrock R
Discov Med; 2012 Jun; 13(73):405-15. PubMed ID: 22742646
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML
J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
